InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.90
(
0.15%
)
US TECH 100
17,679.65
(
0.22%
)
Dow Jones
39,513.96
(
0.32%
)
Brent Oil
82.73
(
-1.46%
)
Bitcoin
60,668.74
(
-3.77%
)
Post# of 251786
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119608
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: WorstLuck post# 201986

Monday, 06/13/2016 4:17:57 PM

Monday, June 13, 2016 4:17:57 PM

Post# of 251786
RVNC—My post from one year ago (#msg-114249260):

I’m skeptical of RT001… I don’t think a topical product will work well in cosmetic applications.

If it were up to me, RVNC would drop RT001 completely and focus on RT002, the (long-acting) injected botulinum toxic that figures to be strong competition for Botox.

In other words, I’m ok with today’s decision to discontinue clinical development of RT001 and focus all resources on RT002.

Press release:
http://finance.yahoo.com/news/revance-reports-results-rt001-topical-200100770.html

CC at 4:30pm ET.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up